Joe Mymryk

Dr. Joe Mymryk

Departments of Oncology, Otolaryngology and Microbiology & Immunology, Western University, London, ON, Canada
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2008 in Journal of Virology
Verified
Journal Article
Closed access
PPPeter Pelka
Peter Pelka
JAJailal N. G. Ablack
Jailal N. G. Ablack
GFGregory J. Fonseca
Gregory J. Fonseca
AYAhmed F. Yousef
Ahmed F. Yousef
Joe MymrykJoe Mymryk
Joe Mymryk

17 June 2003 in Oncogene
Verified
Journal Article
Closed access
NANikita Avvakumov
Nikita Avvakumov
JTJoe Torchia
Joe Torchia
Joe MymrykJoe Mymryk
Joe Mymryk

26 April 2011 in Small
Verified
Journal Article
Open access
PDF file
NSNicole Steinmetz
Nicole Steinmetz
AAAmber L. Ablack
Amber L. Ablack
JHJennifer L. Hickey
Jennifer L. Hickey
JAJailal Ablack
Jailal Ablack
BMBhavik Manocha
Bhavik Manocha
JLJohn D. Lewis
John D. Lewis
Multivalent nanoparticles have several key advantages in terms of solubility, binding avidity, and uptake, making them particularly well suited to molecular imaging applications. Herein is reported the stepwise synthesis and characterization of NIR viral nanoparticles targeted to gastrin‐releasing peptide receptors that are over‐expressed in human prostate cancers. The pan‐bombesin analogue, [β‐Ala11, Phe13, Nle14]bombesin‐(7–14), is conjugated to cowpea mosaic virus particles functionalized with an NIR dye (Alexa Fluor 647) and polyethylene glycol (PEG) using the copper(I)‐catalyzed azide‐alkyne cycloaddition reaction. Targeting and uptake in human PC‐3 prostate cells is demonstrated in vitro. Tumor homing is observed using human prostate tumor xenografts on the chicken chorioallantoic membrane model using intravital imaging. Further development of this viral nanoparticle platform may open the door to potential clinical noninvasive molecular imaging strategies.

5 July 2018 in mBio
Verified
Journal Article
Open access
PDF file
CKCason R. King
Cason R. King
AZAli Zhang
Ali Zhang
TTTanner M. Tessier
Tanner M. Tessier
SGSteven F. Gameiro
Steven F. Gameiro
Joe MymrykJoe Mymryk
Joe Mymryk
As obligate intracellular parasites, viruses are dependent on their infected hosts for survival. Consequently, viruses are under enormous selective pressure to utilize available cellular components and processes to their own advantage. As most, if not all, cellular activities are regulated at some level via protein interactions, host protein interaction networks are particularly vulnerable to viral exploitation. Indeed, viral proteins frequently target highly connected “hub” proteins to “hack” the cellular network, defining the molecular basis for viral control over the host. This widespread and successful strategy of network intrusion and exploitation has evolved convergently among numerous genetically distinct viruses as a result of the endless evolutionary arms race between pathogens and hosts. Here we examine the means by which a particularly well-connected viral hub protein, human adenovirus E1A, compromises and exploits the vulnerabilities of eukaryotic protein interaction networks. Importantly, these interactions identify critical regulatory hubs in the human proteome and help define the molecular basis of their function.

4 November 2022 in Trends in Molecular Medicine
Verified
Journal Article
Open access
KMKatelyn M. MacNeil
Katelyn M. MacNeil
MDMackenzie J. Dodge
Mackenzie J. Dodge
AEAndris M. Evans
Andris M. Evans
TTTanner M. Tessier
Tanner M. Tessier
JWJason Brice Weinberg
Jason Brice Weinberg
Joe MymrykJoe Mymryk
Joe Mymryk
The consequences of human adenovirus (HAdV) infections are generally mild. However, despite the perception that HAdVs are harmless, infections can cause severe disease in certain individuals, including newborns, the immunocompromised, and those with pre-existing conditions, including respiratory or cardiac disease. In addition, HAdV outbreaks remain relatively common events and the recent emergence of more pathogenic genomic variants of various genotypes has been well documented. Coupled with evidence of zoonotic transmission, interspecies recombination, and the lack of approved AdV antivirals or widely available vaccines, HAdVs remain a threat to public health. At the same time, the detailed understanding of AdV biology garnered over nearly 7 decades of study has made this group of viruses a molecular workhorse for vaccine and gene therapy applications.

1 April 2021 in Antiviral Research
Verified
Journal Article
Closed access
MDMackenzie J. Dodge
Mackenzie J. Dodge
KMKatelyn M. MacNeil
Katelyn M. MacNeil
TTTanner M. Tessier
Tanner M. Tessier
JWJason Brice Weinberg
Jason Brice Weinberg
Joe MymrykJoe Mymryk
Joe Mymryk